Showing 601 - 620 results of 1,475 for search '"cancer"', query time: 0.08s Refine Results
  1. 601
  2. 602
  3. 603
  4. 604
  5. 605
  6. 606

    GGCT participates in the malignant process of hepatocellular cancer cells by regulating the PTEN/PI3K/AKT pathway through binding to EZH2 by Junbo He, Liangzhi Wang, Mengjia Lv, Yiming Yuan

    Published 2025-02-01
    “…Abstract Background γ-Glutamylcyclotransferase (GGCT) is implicated in multiple types of cancer diseases. Nevertheless, the roles and relevant mechanisms of GGCT in hepatocellular carcinoma (HCC) remain vague. …”
    Get full text
    Article
  7. 607
  8. 608
  9. 609
  10. 610
  11. 611

    Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States by Monica Kobayashi, Jamie Garside, Joehl Nguyen

    Published 2023-11-01
    “…**Background:** Endometrial cancer (EC) represents a substantial economic burden for patients in the United States. …”
    Get full text
    Article
  12. 612

    Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting by Benjamin H. Lowentritt, Carmine Rossi, Erik Muser, Frederic Kinkead, Bronwyn Moore, Patrick Lefebvre, Dominic Pilon, Shawn Du

    Published 2024-08-01
    “…**Background:** The use of androgen receptor signaling inhibitors, including apalutamide, in combination with androgen deprivation therapy is recommended for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). …”
    Get full text
    Article
  13. 613

    Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota by Min Yang, Jia Guo, Jinxian Li, Shuyue Wang, Yuan Sun, Ying Liu, Yinghua Peng

    Published 2025-02-01
    “…In contrast, plant-derived extracellular vesicles (PEVs) exhibit promising potential in cancer therapy due to their negligible systemic toxicity, high bioavailability and cost- effectiveness. …”
    Get full text
    Article
  14. 614
  15. 615
  16. 616
  17. 617
  18. 618
  19. 619

    Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study by Jason C Hsu, Chen-Fang Wei, Szu-Chun Yang

    Published 2019-03-01
    “…Interventions Targeted therapies have been proven to provide clinical benefits to patients with metastatic non-small cell lung cancer (NSCLC). Gefitinib was initially approved and reimbursed as a third-line therapy for patients with advanced NSCLC by the Taiwan National Health Insurance (NHI) in 2004; subsequently it became a second-line therapy (in 2007) and further a first-line therapy (in 2011) for patients with epidermal growth factor receptor mutation-positive advanced NSCLC. …”
    Get full text
    Article
  20. 620